Abstract
Transcatheter aortic valve implantation (TAVI) has become the standard treatment of severe aortic valve stenosis for patients at high or intermediate operative risk. Percutaneous transfemoral (TF) access is the preferred route owing its low invasiveness and lower perioperative morbidity and mortality compared with the transapical, axillary, aortic approach. However, vascular access complications (VACs) occurring from TF access have been associated with prolonged hospitalization and 30-day mortality.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
